Abstract: Systems and methods for customer journey orchestration are described. One or more aspects of the systems and methods include identifying, by a customer journey orchestration application, a customer journey having a previously unidentified fault; initiating, by a mode selection component, a debug mode of the customer journey orchestration application for the customer journey; receiving, by a graphical user interface of the customer journey orchestration application, a user input corresponding to an event of a plurality of events of the customer journey; simulating, by an event simulation component, the event based on the user input and the debug mode; determining, by a status component, a status of the event based on the simulation; and identifying, by a fault identification component, the previously unidentified fault based on the status of the event.

Abstract: Disclosed are techniques for wireless positioning. In an aspect, a wireless device receives one or more radio frequency (RF) signals from a transmitter device, displays a first arrow and a second arrow on a user interface of the wireless device, a direction of the first arrow representing a first angle-of-arrival (AoA) estimate of the one or more RF signals, and a direction of the second arrow representing a mirror AoA estimate of the first AoA estimate, and displays one or more notifications on the user interface instructing a user of the wireless device to move the wireless device until the direction of the first arrow is aligned with the direction of the second arrow.

Abstract: A biocompatible intravaginal device adapted for the delivery of therapeutic active ingredients (agents) is provided. The device is constructed to be insertable and remain in the vagina for up to a month (28 to 31 days) or more. The device is loaded with the active agents prior to insertion and constructed to continuously release a therapeutically effective amount of the agents during the duration of up to a one month insertion. Preferred agents include contraceptive and anti-infection agents. It is preferred that the agents are non-hormonal.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.

Abstract: An intravaginal contraceptive device has a biocompatible support structure constructed and configured to be inserted into a mammal's vagina without substantially blocking the cervix, coated by a multilayer coating having one or more biodegradable polymers. The multilayer coating can be constructed and formed of materials such that the multilayer coating dissolves over a period of at least three days, wherein each layer of the multilayer coating includes a spermicidal and/or spermiostatic composition and is constructed and formed to dissolve at varying times. Additionally, the multilayer coating is preferably constructed and formed of materials effective to provide a sustained release of a spermicidally or spermiostatically effective amount of the composition for at least three days.

Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine.